Patents
Patents for C12N 15 - Mutation or genetic engineering; Dna or rna concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor (402,210)
06/2005
06/07/2005US6902914 Ligation of nucleotide sequence in sample; obtain nucleotide sequence sample, incubate with primer, polymerase and nucleotide triphosphates, amplify sequences, digest, ligate and recover nucleotide sequence product
06/07/2005US6902913 Recombinant narbonolide polyketide synthase
06/07/2005US6902908 Polypeptides, fusion proteins; includes production and use recombinant expression constructs having regulated promoter; mitochondria
06/07/2005US6902907 Cystic fibrosis gene
06/07/2005US6902906 Bacteria attenuated by a non-reverting mutation in each of the aroC, ompF and ompC genes, useful as vaccines
06/07/2005US6902899 Detection of human papillomaviruses
06/07/2005US6902896 Zinc finger proteins; genomes
06/07/2005US6902885 For detecting viral and cellular polypeptide interactions
06/07/2005US6902736 Isolation and characterization of the csa operon (ETEC-CS4 pili) and methods of using same
06/07/2005US6902734 Also an IL-12 anti-idiotype antibody to the antibody
06/07/2005US6902731 Transcription factors; for arterial administration via stent
06/07/2005US6902730 Semaphorin gene: Semaphorin W
06/07/2005US6902705 Device comprising a plurality of analysis sites on a support
06/07/2005US6902680 Apparatus for use in the isolation, separation, and purification of biopolymers mixtures
06/07/2005US6902657 Electrophoresis separation media and methods
06/07/2005CA2286874C Uses of calculus
06/07/2005CA2270872C Nematode-inducible regulatory dna sequences
06/07/2005CA2270593C Subtilase variants and compositions
06/07/2005CA2266978C Methods and compositions for sensitive and rapid, functional identification of genomic polynucleotides and use for cellular assays in drug discovery
06/07/2005CA2197651C Or-1 on orphan receptor belonging to the nuclear receptor family
06/07/2005CA2153135C Method for obtaining modified immunoglobulins with reduced immunogenicity of murine antibody variable domains and compositions containing them
06/05/2005CA2449186A1 Generation of therapeutic regulatory dc by multiple gene silencing through induction of rna interference
06/04/2005CA2486900A1 A method for obtaining circular mutated and/or chimaeric polynucleotides
06/02/2005WO2005049853A2 Compositions and methods for screening pro-apoptotic compounds
06/02/2005WO2005049850A2 Compositions and methods for systemic nucleic acid sequence delivery
06/02/2005WO2005049846A2 Mutant herpes simplex virus and use thereof in the treatment of squamous cell cancer
06/02/2005WO2005049845A2 Oncolytic herpes simplex virus encoding a heterologous nitroreductase
06/02/2005WO2005049844A2 Vectors, mutant viruses and methods for generating mutant viruses
06/02/2005WO2005049843A2 Plant cells and plants with increased resistance to stress
06/02/2005WO2005049842A2 Improved targeted dna insertion in plants
06/02/2005WO2005049841A1 Insect resistance using inhibition of gene expression
06/02/2005WO2005049839A2 Rna virus-derived plant expression system
06/02/2005WO2005049838A2 Syk-targeted nucleic acid interference
06/02/2005WO2005049835A1 Ice recrystallisation inhibition protein or antifreeze proteins from deschampsia, lolium and festuca species of grass
06/02/2005WO2005049834A1 Cell activator, hair growth stimulant and hair growth promoter
06/02/2005WO2005049832A2 FcϜRIIA-SPECIFIC NUCLEIC ACID INTERFERENCE
06/02/2005WO2005049831A1 Method
06/02/2005WO2005049830A1 METHOD OF DESIGNING siRNA
06/02/2005WO2005049828A1 Nucleic acids specifically binding bioactive ghrelin
06/02/2005WO2005049825A1 Method of detecting signal transduction by g protein-coupled receptor using germination baculovirus
06/02/2005WO2005049824A1 Hollow nanoparticle presenting biological structure-recognition sites, method of producing the same and utilization of the same
06/02/2005WO2005049823A1 Secretory protein production system
06/02/2005WO2005049821A1 METHOD OF EVALUATING RNAi ACTIVITY AND miRNA ACTIVITY
06/02/2005WO2005049817A2 Self-cleaving ribozymes and uses thereof
06/02/2005WO2005049814A2 Novel atypical pneumonia-causing virus
06/02/2005WO2005049808A1 Method for producing l-amino acid by fermentation
06/02/2005WO2005049807A1 Modification of protein glycosylation in methylotrophic yeast
06/02/2005WO2005049805A2 Fructose-bisphosphate aldolase regulatory sequences for gene expression in oleaginous yeast
06/02/2005WO2005049799A2 Chimeric chemokine receptor polypeptides
06/02/2005WO2005049795A2 Mammalian cell lines for detecting, monitoring, and optimizing oligonucleotide-mediated chromosomal sequence alteration
06/02/2005WO2005049793A2 Methods and compositions for combinatorial approaches to cancer gene therapy
06/02/2005WO2005049790A2 Skn-1 and gsk-3 genes and proteins
06/02/2005WO2005049789A2 Synthetic mammalian retrotransposon gene
06/02/2005WO2005049788A2 Reprogramming of somatic cell nuclei
06/02/2005WO2005049787A2 Compositions and methods for in vitro sorting of molecular and cellular libraries
06/02/2005WO2005049652A2 Methods of generating antibody diversity in vitro
06/02/2005WO2005049651A2 Cancer diagnosis and therapy
06/02/2005WO2005049646A2 “seedy1” nuceic acids for making plants having changed growth characteristics
06/02/2005WO2005049644A2 Tool for the transfer and production of proteins using the pseudomonas type iii secretion system
06/02/2005WO2005049639A2 Compositions and methods for protein isolation
06/02/2005WO2005049630A2 Antisense modulation of kinesin-like 1 expression
06/02/2005WO2005049094A1 A mixed complementary viral vector for gene therapy
06/02/2005WO2005049092A1 Ocular tissue modification
06/02/2005WO2005048997A1 Nanoparticles for delivery of a pharmacologically active agent
06/02/2005WO2005048957A2 Novel insertion sites in pox vectors
06/02/2005WO2005048943A2 Compositions and methods for synergistic induction of antitumor immunity
06/02/2005WO2005048914A2 Dna vaccines encoding hsp60 peptide fragments for treating autoimmune diseases
06/02/2005WO2005048913A2 Mutant lrp5/6 wnt-signaling receptors in cancer diagnosis, prognosis and treatment
06/02/2005WO2005048733A2 Methods of producing specialty grain to segment markets
06/02/2005WO2005048693A2 Plant with improved drought tolerance
06/02/2005WO2005048692A2 Tomatoes having reduced deoxyhypusine synthase activity caused by non-transgenic alterations in a deoxyhypusine synthase gene
06/02/2005WO2005035769A3 Gene silencing by using micro-rna molecules
06/02/2005WO2005028675A3 Methods for detecting, diagnosing and treating hepatocellular carcinomas (hcc)
06/02/2005WO2005028625A3 Consensus/ancestral immunogens
06/02/2005WO2005026368A3 Dihydroflavonol-4-reductase
06/02/2005WO2005024044A3 Method for the production of fusion proteins in transgenic mammal milk
06/02/2005WO2005018575A3 Estrogen receptor modulators and uses thereof
06/02/2005WO2005014836A3 Chimaeric vector system
06/02/2005WO2005013889A9 Truncated fragments of alpha-synuclein in lewy body disease
06/02/2005WO2005012483A3 Vpr selective rnai agents and methods for using the same
06/02/2005WO2005010188A3 Rnas able to modulate chromatin silencing
06/02/2005WO2005009463A3 Antigen-presenting cell vaccines and methods of use thereof
06/02/2005WO2005007845A3 Transgenic cells
06/02/2005WO2005005637A3 Herpes simplex virus comprising a genetically modified glycoprotein d
06/02/2005WO2005005613A3 Dsrna induced specific and non-specific immunity in crustaceans and other invertebrates and biodelivery vehicles for use therein
06/02/2005WO2005002509A3 Dna vectors
06/02/2005WO2005001110A3 Transcriptional regulation of gene expression by small double-stranded modulatory rna
06/02/2005WO2005001099A8 Protein expression system
06/02/2005WO2004101741A3 Transgenic plants with increased glycine-betaine
06/02/2005WO2004096984A3 Preservation of rna in a biological sample
06/02/2005WO2004096136A3 Compositions comprising cationic microparticles and hcv e1e2 dna and methods of use thereof
06/02/2005WO2004092384A3 Means and methods for diagnosing and treating affective disorders
06/02/2005WO2004081025A3 Differential megaplex immunoassay
06/02/2005WO2004076648A3 Clinically relevant animal model of human breast cancer and vegf involement in desmoplastic response.
06/02/2005WO2004076633A3 Hypoxia inducible vegf plasmid for ischemic disease
06/02/2005WO2004076625A3 Method of identifying plant cells transformed with a gene
06/02/2005WO2004074507A8 Method to confer cell culture replication activity to different hepatitis c virus isolates
06/02/2005WO2004070003A3 Methods for selecting and screening for trasformants
06/02/2005WO2004066947B1 Hyperthermia oncolysis co-therapy
06/02/2005WO2004058940A9 Sirna-mediated gene silencing